Tags

Type your tag names separated by a space and hit enter

The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement.
Alzheimers Dement. 2017 May; 13(5):561-571.AD

Abstract

INTRODUCTION

The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI-3, which began on August 1, 2016, is a 5-year renewal of the current ADNI-2 study.

METHODS

ADNI-3 will follow current and additional subjects with normal cognition, mild cognitive impairment, and AD using innovative technologies such as tau imaging, magnetic resonance imaging sequences for connectivity analyses, and a highly automated immunoassay platform and mass spectroscopy approach for cerebrospinal fluid biomarker analysis. A Systems Biology/pathway approach will be used to identify genetic factors for subject selection/enrichment. Amyloid positron emission tomography scanning will be standardized using the Centiloid method. The Brain Health Registry will help recruit subjects and monitor subject cognition.

RESULTS

Multimodal analyses will provide insight into AD pathophysiology and disease progression.

DISCUSSION

ADNI-3 will aim to inform AD treatment trials and facilitate development of AD disease-modifying treatments.

Links

PMC Free PDF

Authors+Show Affiliations

Weiner MW
Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, CA, USA; Department of Radiology, University of California, San Francisco, CA, USA; Department of Medicine, University of California, San Francisco, CA, USA; Department of Psychiatry, University of California, San Francisco, CA, USA; Department of Neurology, University of California, San Francisco, CA, USA. Electronic address: michael.weiner@ucsf.edu.
Veitch DP
Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, CA, USA.
Aisen PS
Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, CA, USA.
Beckett LA
Division of Biostatistics, Department of Public Health Sciences, University of California, Davis, CA, USA.
Cairns NJ
Knight Alzheimer's Disease Research Center, Washington University School of Medicine, Saint Louis, MO, USA; Department of Neurology, Washington University School of Medicine, Saint Louis, MO, USA.
Green RC
Division of Genetics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Harvey D
Division of Biostatistics, Department of Public Health Sciences, University of California, Davis, CA, USA.
Jack CR
Department of Radiology, Mayo Clinic, Rochester, MN, USA.
Jagust W
Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, CA, USA.
Morris JC
Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, CA, USA.
Petersen RC
Department of Neurology, Mayo Clinic, Rochester, MN, USA.
Salazar J
Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, CA, USA.
Saykin AJ
Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA.
Shaw LM
Tailored Therapeutics, Eli Lilly and Company, Indianapolis, IN, USA.
Toga AW
Laboratory of Neuroimaging, Institute of Neuroimaging and Informatics, Keck School of Medicine of University of Southern California, Los Angeles, CA, USA.
Trojanowski JQ
Institute on Aging, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Alzheimer's Disease Core Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Udall Parkinson's Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Research, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Alzheimer's Disease Neuroimaging Initiative
No affiliation info available

MeSH

Alzheimer DiseaseBiomarkersBrainClinical Trials as TopicDisease ProgressionHumansMagnetic Resonance ImagingNeuroimagingPositron-Emission TomographyRadionuclide Imaging

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

27931796

Citation

Weiner, Michael W., et al. "The Alzheimer's Disease Neuroimaging Initiative 3: Continued Innovation for Clinical Trial Improvement." Alzheimer's & Dementia : the Journal of the Alzheimer's Association, vol. 13, no. 5, 2017, pp. 561-571.
Weiner MW, Veitch DP, Aisen PS, et al. The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement. Alzheimers Dement. 2017;13(5):561-571.
Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Morris, J. C., Petersen, R. C., Salazar, J., Saykin, A. J., Shaw, L. M., Toga, A. W., & Trojanowski, J. Q. (2017). The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement. Alzheimer's & Dementia : the Journal of the Alzheimer's Association, 13(5), 561-571. https://doi.org/10.1016/j.jalz.2016.10.006
Weiner MW, et al. The Alzheimer's Disease Neuroimaging Initiative 3: Continued Innovation for Clinical Trial Improvement. Alzheimers Dement. 2017;13(5):561-571. PubMed PMID: 27931796.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement. AU - Weiner,Michael W, AU - Veitch,Dallas P, AU - Aisen,Paul S, AU - Beckett,Laurel A, AU - Cairns,Nigel J, AU - Green,Robert C, AU - Harvey,Danielle, AU - Jack,Clifford R,Jr AU - Jagust,William, AU - Morris,John C, AU - Petersen,Ronald C, AU - Salazar,Jennifer, AU - Saykin,Andrew J, AU - Shaw,Leslie M, AU - Toga,Arthur W, AU - Trojanowski,John Q, AU - ,, Y1 - 2016/12/05/ PY - 2016/07/25/received PY - 2016/10/24/revised PY - 2016/10/31/accepted PY - 2016/12/10/pubmed PY - 2017/12/19/medline PY - 2016/12/10/entrez KW - Alzheimer's disease KW - Amyloid phenotyping KW - Brain Health Registry KW - Centiloid method KW - Clinical trial biomarkers KW - Functional connectivity KW - Tau imaging SP - 561 EP - 571 JF - Alzheimer's & dementia : the journal of the Alzheimer's Association JO - Alzheimers Dement VL - 13 IS - 5 N2 - INTRODUCTION: The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI-3, which began on August 1, 2016, is a 5-year renewal of the current ADNI-2 study. METHODS: ADNI-3 will follow current and additional subjects with normal cognition, mild cognitive impairment, and AD using innovative technologies such as tau imaging, magnetic resonance imaging sequences for connectivity analyses, and a highly automated immunoassay platform and mass spectroscopy approach for cerebrospinal fluid biomarker analysis. A Systems Biology/pathway approach will be used to identify genetic factors for subject selection/enrichment. Amyloid positron emission tomography scanning will be standardized using the Centiloid method. The Brain Health Registry will help recruit subjects and monitor subject cognition. RESULTS: Multimodal analyses will provide insight into AD pathophysiology and disease progression. DISCUSSION: ADNI-3 will aim to inform AD treatment trials and facilitate development of AD disease-modifying treatments. SN - 1552-5279 UR - https://www.unboundmedicine.com/medline/citation/27931796/The_Alzheimer's_Disease_Neuroimaging_Initiative_3:_Continued_innovation_for_clinical_trial_improvement_ DB - PRIME DP - Unbound Medicine ER -